Clinical Trial Update: Serologic Response to the SARS-CoV-2 (COVID-19) MRNA-1273 Vaccine in Select Subsets of Oncology Patients

View source ↗

Summary

Completed clinical trial update on serologic response to the Moderna COVID-19 vaccine (mRNA-1273) in select oncology patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Spikevax (mRNA-1273)

Snippet

Sponsor: University of Rochester | Conditions: Covid19, Cancer | Status: COMPLETED